Arcellx, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arcellx, Inc. - overview
Established
2014
Location
Rockville, MD, US
Primary Industry
Biotechnology
About
Arcellx, Inc. is a US-based biotechnology company focused on developing innovative cell therapies targeting cancer and autoimmune diseases, utilizing proprietary technology to enhance treatment precision and efficacy. Founded in 2014 and headquartered in Gaithersburg, US, Arcellx, Inc. specializes in biopharmaceuticals aimed at treating cancer and autoimmune diseases.
The company has raised USD 100. 00 mn through multiple funding rounds, with the most recent PIPE round closing on February 3, 2022, involving Kite Pharma, Inc. David Hilbert, the CEO and founder, has been instrumental in the company's strategic direction since its inception. In February 2026, Gilead Sciences, Inc.
agreed to acquire Arcellx Inc. for USD 7. 8 billion. Arcellx specializes in innovative cell therapies targeting cancer and autoimmune diseases, leveraging its proprietary D-Domain technology in conjunction with its ddCAR and ARC-SparX platforms.
These core offerings aim to enhance the efficacy of cancer treatment by enabling precise targeting and destruction of malignant cells. The therapies are in various stages of clinical development, addressing significant unmet medical needs in oncology, particularly for relapsed and refractory conditions, and are designed for multiple cancer types, including multiple myeloma. Arcellx operates in the US and Europe, engaging with healthcare providers, research institutions, and patients seeking advanced treatment options. In the most recent fiscal year, 2024, Arcellx reported revenue of USD 107.
94 mn, with an EBITDA of -USD 132. 38 mn. The company generates revenue through partnerships and collaborations with healthcare institutions and pharmaceutical companies, structured around clinical trial agreements and supply arrangements. Arcellx plans to utilize its recent funding of USD 100.
00 mn from the PIPE round to advance its pipeline of adaptive and controllable cell therapies, focusing on the development of CART-ddBCMA. The company aims to initiate a Phase 1 study in acute myeloid leukemia (AML) within 2022, reflecting its commitment to expanding its therapeutic offerings. Furthermore, Arcellx is exploring opportunities for market expansion, particularly targeting regions in Europe and North America for broader access to its innovative therapies.
Current Investors
New Enterprise Associates, SR One, Novo Holdings
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.arcellx.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Arcellx, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Public to Private, Trade Sale | Announced | Arcellx, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.